The cost-effectiveness of sertraline in the treatment of depression

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2497-2508

  Olvey, Eleanor L ^a   Skrepnek, Grant H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cost effectiveness; Cost utility; Depression; Pharmacoeconomics; Sertraline

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DOSULEPIN; ESCITALOPRAM; FLUOXETINE; GENERIC DRUG; HETEROCYCLIC COMPOUND; IMIPRAMINE; LOFEPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; HUMAN; MANAGED CARE ORGANIZATION; OUTPATIENT CARE; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; DEPRESSION; ECONOMICS, PHARMACEUTICAL; HUMANS; PATIENT COMPLIANCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; UNITED STATES;

EID: 54349103982     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2497     Document Type: Review

References (70)

1. World Health Organization. Mental health: new understanding, new hope. The world health report 2001. Geneva: World Health Organization; 2001
2. Kruijshaar M, Hoeymans N, Spijker J, et al. Has the burden of depression been overestimated? Bull World Health Organ 2005;83:443-8
3. Robins LN, Regier DA, editors. Psychiatric disorders in America, The Epidemiologic Catchment Area Study. New York: The Free Press; 1990
4. Ohayon M, Schatzberg A. Fine-tuning our diagnosis and treatment of depression: editorial. J Psychiatr Res 2006;40:281-2
5. Hasin DS, Goodwin RD, Stinson FS, et al. The epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2005;62:1097-106
6. National Institute of Mental Health. Depression. NIH Publication 07-3561. Bethesda, MD: US Department of Health and Human Services; 2007
7. Lyness JM, Niculescu A, Tu X, et al. The relationship of medical comorbidity and depression in older, primary care patients. Psychosomatics 2006;47:435-9
8. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry 1998;55:580-92
9. Alexander JL, Dennerstein L, Kotz K, et al. Women, anxiety; and mood: a review of the nomenclature, comorbidity, and epidemiology. Expert Rev Neurother 2007;7:45s-54s
10. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
11. Luppa M, Heinrich S, Angermeyer MC, et al. Cost-of-illness studies of depression: a systematic review. J Affect Disord 2007;98:29-43
12. Simon GE, Von Korff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med 1995;4:99-105
13. Henk HJ, Katzelnick DJ, Kobak KA, et al. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry 1996;53:899-904
14. US Department of Health and Human Services. Health, United States, 2007, With chartbook on trends in the health of Americans. Hyattsville, MD: National Center for Health Statistics; 2007
15. Zoloft (sertraline HCI). Pfizer Inc. 2008. Available from: http://www.zoloft.com [Accessed 16 June 2008]
16. DrugsΦDA. US Food and Drug Administration Center for Drug Evaluation and Research. 2008. Available from: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm [Accessed 16 Jun 2008]
17. Cherry DK, Woodwell DA. Rechtsteiner EA. National Ambulatory Medical Care Survey: 2005 summary. Advance data from vital and health statistics, Number 387. Hyattsville, MD: National Center for Health Statistics; 2007
18. Top 200 brand name drugs by units in 2006. Drug Topics. 2007. Available from: http://drugtopics.modernmedicine.com/drugtopics/data/ articlestandard//drugtopics/092007/407649/article.pdf [Accessed 7 Jan 2008]
19. Top 200 brand name drugs by units in 2006. Drug Topics. 2007. Available from: http://drugtopics.modernmedicine.com/drugtopics/data/ articlestandard/drugtopics/092007/407652/article.pdf [Accessed 7 Jan 2008]
20. Bootman JL, Townsend RJ, McGhan WF. Introduction to pharmacoeconomics. 3rd edition. In: Bootman JL, Townsend RJ, McGhan WF, editors, Principles of pharmacoeconomics. Cincinnatti, OH: Harvey Whitney; 2005
21. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. J Am Med Assoc 2001;286:2947-55
22. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia: American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000;132:738-42
23. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32
24. Kasper S, Heiden R. Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol 1995;10:163-s172
25. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 1993;306:683-7
26. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36
27. Einarson TR, Arikian S, Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995;17:136-53
28. Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997;12:286-96
29. Doyle JJ, Casciano J, Arikian S, et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001;4:16-31
30. Freeman H, Arikian S, Lenox-Smith A. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 2000;18:143-8
31. Casciano R. A pharmacoeconomic evaluation of major depressive disorder. Manag Care Interface 2003;(Suppl B):16-21
32. Wan GJ, Crown WH, Berndt ER, et al. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. Int J Clin Pract 2002;56:434-9
33. Monfared AA, Han D, Sheehy O, et al. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study. Curr Med Res Opin 2006;22:83-94
34. Smith W, Sherrill A. A pharmacoeconomic study of the management of major depression: patients in a TennCare HMO. Med Interface 1996;9:88-92
35. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. Br Med J 1994;309:249-53
36. Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand 1998;97:241-52
37. Kendrick T, Peveler R, Longworth L, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Br J Psychiatry 2006;188:337-45
38. Canadian Coordinating Office for Health Technology Assessment. Selective serotonin reuptake inhibitors (SSRIs) for major depression. Part II. The cost-effectiveness of SSRIs in treatment of depression. CCOHTA Report 1997: 3E. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997
39. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995;10:41s-48s
40. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. Br J Med Econ 1994;7:67-79
41. Stewart A. Revisiting the relative cost-effectiveness of selective serotonin re-uptake inhibitors and tricyclic antidepressants: what price inflation and subtherapeutic dosages? Br J Med Econ 1996;10:203-16
42. Skrepnek GH. Cost-effectiveness analysis. Third edition. In: Bootman JL, Townsend RJ, McGhan WF, editors, Principles of pharmacoeconomics. Cincinnatti, OH: Harvey Whitney; 2005
43. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996;38:97-111
44. Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm 2007;13:8s-18s
45. Shih YC, Bekele NB, Xu Y. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Pharmacoeconomics 2007;25:843-62
46. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994;5:249-68
47. Serrano-Blanco A, Pinto-Meza A, Suarez D, et al. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. Acta Psychiatr Scand 2006;432:39s-47s
48. Armstrong EP, Skrepnek GH, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2007;23:251-8
49. Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized comparative clinical trial. Curr Med Res Opin 2007;23:245-50
50. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998;13:157-69
51. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998;47:71-9
52. Russell JM, Berndt ER, Miceli R, et al. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. Am J Manag Care 1999;5:597-606
53. Crown WH, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001;4:295-307
54. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 1995;23:395-412
55. Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999;19:47-s54
56. Berndt ER, Russell JM, Miceli R, et al. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Value Health 2000;3:208-21
57. Sheehan DV, Eaddy MT, Shah MB, et al. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care 2005;11:354s-361s
58. Poret AW, Neslusan C, Ricci JF, et al. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. Value Health 2001;4:362-9
59. Skaer TL, Sclar DA, Robison LM, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995;56:556-67
60. Eilon S. Incremental Calculus and its Applications. IMA J Math Appl Bus Indust 1990;2:109-26
61. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008;299(15):1833-5
62. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506
63. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60
64. McCombs J. Managing antidepressant drug therapy in an evolving marketplace. Am J Manag Care 1994;10:173s-178s
65. Beyer JL. Managing depression in geriatric populations. Ann Clin Psychiatry 2007;19:221-38
66. Calles JL. Depression in children and adolescents. Prim Care Clin Office Pract 2007;34:243-58
67. Tierney JG. Treatment-resistant depression: managed care considerations. J Manag Care Pharm 2007;13:2s-7s
68. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70
69. Haby MM, Tonge B, Littlefield L, et al. Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents. Aust N Z J Psychiatry 2004;38:579-91
70. Skrepnek GH. The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analyses. Pharmacoeconomics 2007;25:649-64